The Phase IIb failure of Teva Pharmaceutical Industries Ltd./Xenon Pharmaceuticals Inc.’s TV-45070 pain ointment in osteoarthritis is another blow for the once very promising Nav1.7 target, but some consultants advise not to rule the class out yet in other indications.
TV-45070 is a small molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system, according to the sponsors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?